Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
about
Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.CYP3A activity: towards dose adaptation to the individual.Integrated semi-physiological pharmacokinetic model for both sunitinib and its active metabolite SU12662.Use of microdose phenotyping to individualise dosing of patients.Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.Sunitinib tissue distribution changes after coadministration with ketoconazole in mice.Association of axitinib plasma exposure and genetic polymorphisms of ABC transporters with axitinib-induced toxicities in patients with renal cell carcinoma.Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.Sunitinib treatment in a patient with metastatic renal cell carcinoma and bariatric surgery.
P2860
Q38664221-A4ADDF4E-0F8C-4B41-97FA-7A82A5640AA9Q38763583-0E9DC5C7-B2F6-4363-BD00-5E0D8CFDF9B4Q40126912-2AD58504-1CF4-4F50-AFB8-1964DF6BD61FQ40996401-88D4E961-5D92-4A19-AAB6-E01C89E6BCFBQ47308875-8FE6119E-0FF8-4922-9F63-A9B9F62AC308Q48341764-1DDE3CD5-0ED2-40C2-BA2C-07002F05F5D4Q51537517-07F97083-C72E-4CCD-8B69-F7AF120A6C1EQ53581485-55FFCA6D-39D3-4790-946E-AE507828D5AFQ55053121-9139844C-6863-4BEB-918F-97116A8746C6
P2860
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@en
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@nl
type
label
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@en
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@nl
prefLabel
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@en
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@nl
P2093
P2860
P1476
Midazolam as a phenotyping probe to predict sunitinib exposure in patients with cancer.
@en
P2093
A Sparreboom
H Gelderblom
J M C König-Quartel
J den Hartigh
M den Hollander
N P van Erp
P2860
P2888
P356
10.1007/S00280-013-2322-7
P577
2013-10-23T00:00:00Z